Innovation Pharmaceuticals Inc (IPIX)

[seek the light]

This is important because of the link to UPS:

Shares of Tracon Pharmaceuticals Inc. were up 29% in premarket trading on Friday after the company said it would partner with two Chinese companies to develop its investigational soft tissue sarcoma therapy in North America. The partner companies are 3D Medicines Co. Ltd. and Jiangsu Alphamab Biopharmaceuticals Co. Ltd., both privately held. Tracon will commercialize the treatment, envafolimab, in North America if it's approved. The company said it expects to launch the pivotal trial for envafolimab in the U.S. early next year. "Given the activity of other PD-1 and PD-L1 inhibitors in sarcoma, we believe a registration enabling study of envafolimab in the sarcoma subtype of UPS will be meaningful to patients and providers," Charles Theuer, Tracon's president and CEO, said in a news release. Tracon's stock is down 60% year-to-date. The S&P 500 is up 27%.

Here is a comment that applies to this subject:
This immune checkpoint could be a new target against cancer,
autoimmune diseases
Thursday, January 16, 2020

Inhibitors against PD-1 and CTLA-4 have become well-established anti-cancer treatments. Now, a research team led by Dartmouth College suggests another immune checkpoint, which acts as a “brake” on naive T cells' activation, could also serve as a therapeutic target for cancer and autoimmune diseases.